Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 8/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15871038 | 0.84 | LPO (0.48) | HAO1PTGDR2KMT2AKDM4E | |
| SCHEMBL6330225 | 0.83 | CYP2A6 (0.48) | GRM5 | |
| SCHEMBL6209390 | 0.82 | HAO1 (0.46) | HAO1GRM5PTGDR2 | |
| SCHEMBL6208432 | 0.80 | HAO1 (0.53) | HAO1APPPTGDR2KMT2A | |
| SCHEMBL6208521 | 0.76 | PTGDR2 (0.41) | HAO1GRM5PTGDR2KMT2AKDM4E | |
| SCHEMBL6207508 | 0.76 | PTGDR2 (0.47) | HAO1GRM5PTGDR2KMT2AKDM4E | |
| SCHEMBL15870991 | 0.74 | — | — | |
| SCHEMBL3951095 | 0.71 | PTGS1 (0.43) | KMT2A | |
| SCHEMBL6289336 | 0.70 | GRM5 (0.50) | GRM5APPKMT2AKDM4E | |
| SCHEMBL14960637 | 0.70 | GRM5 (0.45) | GRM5APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2005-06-16 | — | — | US | claimed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | claimed |
| US-6706707-B2 | TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | claimed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | claimed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | claimed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | claimed |
| US-6972299-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMANN-LA ROCHE INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1599204-A2 | SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | Recordati Ireland Limited (IE) | 2005-11-30 | — | — | EP | disclosed |
| US-6927232-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMAN-LA ROCHE INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | disclosed |
| WO-2004067002-A2 | SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | RECORDATI IRELAND LIMITED (IE) | 2004-08-12 | — | — | WO | disclosed |
| US-6706707-B2 | TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-11-06 | — | — | US | disclosed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM6 | HAO1 4762/4885GRM5 1/4885APP 2528/4885 |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | HAO1 4482/4885GRM5 1/4885APP 2993/4885 |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | HAO1 4482/4885GRM5 1/4885APP 2993/4885 |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, HRH4 | HAO1 3992/4885GRM5 1/4885APP 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.